Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
BEDFORD, Mass., April 29, 2024 BUSINESS WIRE Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company's financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his position as Stoke's Chief Financial Officer effective Tuesday, May 7. "I want to thank Mr. Tulipano for his contributions to Stoke over the past five years. He has led multiple financings, including Stoke's highly successful Initial Public Offering in 2019 and the recent $125M public offering and leaves the Company well positioned to execute on our goal of delivering the first potential disease-modifying therapy to patients with Dravet syndrome," said Edward M. Kaye, M.D., Chief
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
STOK
Earnings
- 5/6/24 - Beat
STOK
Sec Filings
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- 5/3/24 - Form 4
- STOK's page on the SEC website